All In Biotech

Drug Trial Radar · NCT01820585

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia: a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jul 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 528 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

528

Actual

Start

Apr 2009

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Bial - Portela C S.A.Industry
Sponsor type
Industry
First posted
Mar 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a double-blind, randomised, placebo-controlled, parallel-group, multicentre, multinational, Phase II study in 528 subjects with pain due to Fibromyalgia syndrome(FMS). Subjects were randomised in a 1:1:1:1 ratio to receive placebo, Eslicarbazepine acetate (ESL) 400 mg once daily (QD), ESL 800 mg QD or ESL 1200 mg QD. The study was carried out as follows.

Conditions

  • Fibromyalgia

Interventions

  • PlaceboDrug

    Tablets

  • ESL 400 mgDrug

    tablets

  • ESL 800 mgDrug

    tablets

  • ESL 1200 mgDrug

    tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline to Endpoint in Mean PainTime frame: Baseline and 13 Weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.